+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Does hormone replacement therapy affect the use of prescription medicines in postmenopausal women: experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757



Does hormone replacement therapy affect the use of prescription medicines in postmenopausal women: experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757



Bjog 114(5): 548-554



To determine how postmenopausal hormone therapy (HRT) is related to the use of other prescription medication. Follow up of a randomised controlled trial with a blind subtrial of hormone therapy versus placebo and a nonblind subtrial of open label hormone therapy versus nontreatment. A total of 1823 postmenopausal women aged 50-64 at the time of sampling participated in the trial from 1999 to 2004. Use of prescription medication was identified by records in the central computerised database of the Estonian Health Insurance Fund. The use of 21 classes of prescription medication was compared in the hormone therapy arms and placebo or nontreatment trial arms. The influence of women's socio-economic characteristics on the intensity of concomitant medication use was also examined. The proportion of women using any prescription medication besides hormone therapy did not differ between the arms. However, the type of prescribed drugs varied between the arms. After combining data from both hormone therapy arms, for women using HRT the combined hazard ratio was 1.26 (95% CI: 1.05-1.53) for the use of calcium channel blockers, 1.48 (95% CI: 1.10-1.99) for local vaginal treatment, 0.70 (95% CI: 0.50-0.99) for hypnotics and sedatives and 0.77 (95% CI: 0.60-0.99) for selective serotonin reuptake inhibitors (SSRIs). Women who were older, who had a higher body mass index, who were unemployed and who lived outside the capital used more prescription drugs in comparison with others. Hormone therapy did not increase the overall use of prescription medication other than hormone therapy, but the types of drugs used in hormone therapy and nontherapy arms varied, with increased use of calcium channel blockers for hypertension and local vaginal treatments for vaginal candidiasis and decreased use of hypnotics, sedatives and SSRIs in the HRT arms.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 048822456

Download citation: RISBibTeXText

PMID: 17355268

DOI: 10.1111/j.1471-0528.2007.01292.x


Related references

Postmenopausal hormone therapy increases use of health services: experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757. American Journal of Obstetrics and Gynecology 195(1): 62-71, 2006

Who wants to join preventive trials?--Experience from the Estonian Postmenopausal Hormone Therapy Trial [ISRCTN35338757. Bmc Medical Research Methodology 5: 12, 2005

Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757. Maturitas 55(2): 162-173, 2006

Treatment adherence in the Estonian postmenopausal hormone therapy (EPHT) trial [ISRCTN35338757. Maturitas 52(3-4): 286-295, 2005

The effect of hormone therapy on women's quality of life in the first year of the Estonian Postmenopausal Hormone Therapy trial. Bmc Research Notes 5: 176, 2013

Effect of hormone replacement therapy on the activities of factor VII and protein C in postmenopausal women women The postmenopausal estrogen/progestin intervention trial. Blood 86(10 SUPPL 1): 200A, 1995

Effects of hormone replacement therapy on endometrial histology in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA (Journal of the American Medical Association) 275(5): 370-375, 1996

Effect of hormone replacement therapy on the validity of the Friedewald equation in postmenopausal women: The Postmenopausal Estrogen/Progestins Interventions (PEPI) trial. Journal of Clinical Epidemiology 52(12): 1187-1195, 1999

Prescription of hormone replacement therapy in postmenopausal women with renal failure. Kidney International 56(6): 2243-2247, 1999

Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 275(5): 370-375, 1996

Hormone replacement therapy does not affect the 24-hour heart rate variability in postmenopausal women: results of a randomized, placebo-controlled trial with two regimens. Pacing and Clinical Electrophysiology 28 Suppl 1: S172-S177, 2005

Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. Journal of Cardiovascular Medicine 10(1): 85-92, 2009

Study of tumor S-phase in postmenopausal women diagnosed with breast cancer while using hormone replacement therapy vs those never having used hormone replacement therapy. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 203, 1996

Experience of hormone replacement therapy in postmenopausal women living with HIV. Post Reproductive Health 2019: 2053369119838737, 2019

Do perceptions of risk and quality of life affect use of hormone replacement therapy by postmenopausal women?. Journal of the American Board of Family Practice 16(4): 270-277, 2003